Skip to main content

Advertisement

SpringerLink
Log in

Bevacizumab Improves Pathological Response of Colorectal Cancer Liver Metastases Treated with XELOX/FOLFOX

  • Colorectal Cancer
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Histological response of colorectal cancer liver metastases to chemotherapy may be graded based on the extent of tumor regression. The knowledge about the effect of bevacizumab, if given in addition to fluoropyrimidines and oxaliplatin, on tumor regression and its consequences on clinical outcome is limited.

Materials and Methods

Resected liver metastases from patients of 2 prospective nonrandomized trials (fluoropyrimidines and oxaliplatin ± bevacizumab) were analyzed retrospectively. Histological response was analyzed according to an established tumor regression grading for colorectal cancer liver metastases. Tumor regression grades (TRGs) were correlated to progression-free and overall survival.

Results

Bevacizumab improved tumor regression to chemotherapy significantly. Improvement in histological response was translated into a significant prolongation of progression-free and overall survival.

Conclusions

Classifying histological response based on tumor regression grades qualifies to predict the outcome of patients with colorectal cancer liver metastases. Tumor regression grading provides a standardized pathological response evaluation, against which radiologic response on chemotherapy including biologicals can be prospectively evaluated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (Eortc Intergroup Trial 40983): A randomised controlled trial. Lancet. 2008;9617:1007–16.

    Article  CAS  Google Scholar 

  2. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;23:2335–42.

    Article  Google Scholar 

  3. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;12:1539–44.

    Article  CAS  Google Scholar 

  4. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;11:1830–5.

    Article  CAS  Google Scholar 

  5. Gruenberger T, Kaczirek K, Bergmann M, Zielinski CC, Gruenberger B. Progression-free survival in a Phase II study of perioperative bevacizumab plus Xelox in patients with potentially curable metastatic colorectal cancer. ASCO annual meeting proceedings, vol 26; 2008. p. 4073

  6. Gruenberger B, Scheithauer W, Punzengruber R, Zielinski C, Tamandl D, Gruenberger T. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer. 2008;1:120.

    Article  CAS  Google Scholar 

  7. Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008;5:814–9.

    Article  Google Scholar 

  8. Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;34:8688–96.

    Article  Google Scholar 

  9. Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008;10:1635–41.

    Article  Google Scholar 

  10. Blazer DG III, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;33:5344–51.

    Article  Google Scholar 

  11. Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;2:299–304.

    Google Scholar 

  12. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;2:145–7.

    Article  CAS  Google Scholar 

  13. Fong Y, Fortner J, Sun RL, Brennan MF and Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;3:309–18 (discussion 318–21).

    Article  Google Scholar 

  14. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;11:2680–6.

    Article  Google Scholar 

  15. Klinger M, Eipeldauer S, Hacker S, et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol. 2009;5:515–20.

    Google Scholar 

  16. Suh KW, Kim JH, Kim do Y, Kim YB, Lee C, Choi S. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the Mthfr or Xrcc1 gene? Ann Surg Oncol. 2006;11:1379–85.

    Article  Google Scholar 

  17. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007;12:2761–7.

    Article  Google Scholar 

  18. Mentha G, Terraz S, Morel P, et al. Dangerous halo after neoadjuvant chemotherapy and two-step hepatectomy for colorectal liver metastases. Br J Surg. 2009;1:95–103.

    Article  Google Scholar 

  19. Bodingbauer M, Tamandl D, Schmid K, Plank C, Schima W, Gruenberger T. Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases. Br J Surg. 2007;9:1133–8.

    Article  Google Scholar 

  20. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;12:2013–9.

    Article  CAS  Google Scholar 

Download references

Acknowledgment

The following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article: Consultant or Advisory Role: Thomas Gruenberger, F. Hoffmann-LaRoche Lt.; Honoraria: Thomas Gruenberger, Birgit Gruenberger F. Hoffmann-LaRoche Ltd.; Research Funding: Thomas Gruenberger, F. Hoffmann-LaRoche Ltd., Sanofi-Aventis.

Author information

Authors and Affiliations

  1. Department of General Surgery, Hepatobiliary Service, Medical University of Vienna, Vienna, Austria

    Markus Klinger MD, Dietmar Tamandl MD, Stefan Hacker MD, Beata Herberger MSc, Klaus Kaczirek MD, Marion Dorfmeister MD & Thomas Gruenberger MD

  2. Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria

    Sandra Eipeldauer MD

  3. Department of Internal Medicine, Barmherzige Brüder Hospital, Vienna, Austria

    Birgit Gruenberger MD

Authors
  1. Markus Klinger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dietmar Tamandl MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sandra Eipeldauer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stefan Hacker MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Beata Herberger MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Klaus Kaczirek MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marion Dorfmeister MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Birgit Gruenberger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Thomas Gruenberger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Gruenberger MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klinger, M., Tamandl, D., Eipeldauer, S. et al. Bevacizumab Improves Pathological Response of Colorectal Cancer Liver Metastases Treated with XELOX/FOLFOX. Ann Surg Oncol 17, 2059–2065 (2010). https://doi.org/10.1245/s10434-010-0972-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-010-0972-9

Keywords

Search

Navigation